

Review

Open Access

Role of the ubiquitin proteasome system in Alzheimer's disease

Sudarshan C Upadhy and Ashok N Hegde*

Address: ¹Department of Neurobiology and Anatomy, Wake Forest University Health Sciences Medical Center Boulevard, Winston-Salem, NC 27157, USA

Email: Ashok N Hegde* - ahegde@wfubmc.edu

* Corresponding author

Published: 22 November 2007

BMC Biochemistry 2007, **8**(Suppl 1):S12 doi:10.1186/1471-2091-8-S1-S12

This article is available from: <http://www.biomedcentral.com/1471-2091/8/S1/S12>

© 2007 Upadhy and Hegde; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Though Alzheimer's disease (AD) is a syndrome with well-defined clinical and neuropathological manifestations, an array of molecular defects underlies its pathology. A role for the ubiquitin proteasome system (UPS) was suspected in the pathogenesis of AD since the presence of ubiquitin immunoreactivity in AD-related neuronal inclusions, such as neurofibrillary tangles, is seen in all AD cases. Recent studies have indicated that components of the UPS could be linked to the early phase of AD, which is marked by synaptic dysfunction, as well as to the late stages of the disease, characterized by neurodegeneration. Insoluble protein aggregates in the brain of AD patients could result from malfunction or overload of the UPS, or from structural changes in the protein substrates, which prevent their recognition and degradation by the UPS. Defective proteolysis could cause the synaptic dysfunction observed early in AD since the UPS is known to play a role in the normal functioning of synapses. In this review, we discuss recent observations on possible links between the UPS and AD, and the potential for utilizing UPS components as targets for treatment of this disease.

Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; <http://www.targetedproteinsdb.com>).

Protein pathway in the disease - Introduction

The ubiquitin proteasome system (UPS) plays a role in a variety of cellular functions. In the UPS, substrate proteins are targeted for degradation by covalent attachment of ubiquitin, which is mediated by an enzymatic cascade consisting of activating (E1), conjugating (E2) and ligating (E3) enzymes. The ubiquitin-conjugated proteins are subsequently degraded by a large multi-subunit complex, the 26S proteasome. Substrate-specific E3s, along with specific E2s, ensure selective protein targeting for proteolysis [1,2]. In the nervous system, the UPS plays a role in normal physiological function, while evidence gathered in the past several years also indicates a role in neurodegenerative diseases such as Alzheimer's disease (AD) [1,2].

In this article, we discuss AD pathogenesis and how the UPS could be linked to the early and late stages of the disease. We also suggest how further research into this area might help to develop therapeutic strategies for AD.

Alzheimer's disease

AD is a neurodegenerative disorder of the CNS, clinically characterized by progressive loss of memory and other cognitive skills, resulting in severe dementia. The condition often begins with mild memory lapses and then gradually advances to dementia: a progressive deterioration of memory, language and most mental functions. During the early stages of AD development, neurological examination is normal except for observed cognitive dysfunctions

such as progressive worsening of memory [3-8]. The intellectual decline is accompanied by the progressive extracellular and intracellular accumulation of insoluble fibrous material in the brain in the form of senile plaques and neurofibrillary tangles (NFTs) [7].

AD is the most prevalent neurodegenerative disorder and the most common cause of dementia [8]. Familial AD is a rare autosomal dominant disease with early onset, caused by mutations in the amyloid precursor protein (APP) and presenilin (PSEN) genes, both of which are linked to amyloid β ($A\beta$) peptide metabolism [9]. $A\beta$ is produced from APP by sequential cleavage involving β -secretase (also known as β -site APP cleaving enzyme 1 (BACE1)) and γ -secretase (presenilin complex), and released into the extracellular spaces [10]. Sporadic AD is a common heterogeneous disease and is caused by a complex interaction of genetic and environmental risk factors [9] (see figure 1).

The pathological signs of both types of AD include the loss of medium and large pyramidal neurons, the presence of plaques and NFTs (composed of deposits of amyloid filaments and hyperphosphorylated tau, respectively, surrounded by altered neurite processes and glia), a degeneration of the neurons and the loss of synapses [11,12]. Tau is a structural protein that is normally associated with microtubuli. In atypical conditions (such as in AD), tau protein synthesis is upregulated and it undergoes an abnormal post-translational modification characterized by hyperphosphorylation. Although multiple genetic disturbances are believed to underlie AD, a major cause of the disease is buildup of the toxic $A\beta$ peptide [13].

The formation of the neurofibrillary lesions is believed to lead to the symptoms of the disease, which result most probably from the degeneration of nerve cells in the cerebral cortex and hippocampal formation, following synaptic loss. Defective synaptic function and memory loss is seen in the early stages of human AD and in animal models of the disease; as such, cognitive deficits are correlated with the loss of synapses [14]. During the early phase of AD there is a 25–35% decrease in the density of synapses and as the disease progresses synaptic loss is more strongly correlated with the disease than the plaques and tangles [15]. Animal models of AD mimic the cognitive impairment seen in human AD [16,17].

Recent studies also suggest that AD begins with subtle alterations in synaptic efficacy prior to neuronal degeneration and that diffusible oligomeric assemblies of $A\beta$ [14] are the cause of this neuronal dysfunction. Although there is eventual synaptic loss in both human AD and animal models of the disease, deficits in spatial memory and inhibition of long-term potentiation (LTP; an electrophysio-

logical measure of synaptic strength) precede morphological alterations in the animal models, suggesting earlier biochemical changes in the disease [14,18,19]. $A\beta$ treatment of cultured hippocampal neurons leads to the inactivation of protein kinase A (PKA). Persistence of its regulatory subunit PKAII alpha suggests that $A\beta$ acts directly on the signaling pathways consisting of cAMP/PKA/cAMP-responsive element binding protein (CREB), which are required for development of late phase LTP [20]. Therefore, agents that enhance the PKA pathway have potential for the treatment of AD [20]. In transgenic mice expressing mutant APP, learning and memory is impaired at 9–10 months of age (although no $A\beta$ plaques are observed in the brains of these mice) [21]. In mice carrying various mutations of APP, both *in vitro* and *in vivo* LTP is impaired much before detectable $A\beta$ deposits are observed [22]. Also, cerebral microinjection of oligomers of $A\beta$ peptide inhibits *in vivo* LTP in rats [23].

The UPS and Alzheimer's disease

Several studies implicate neuronal UPS in the pathogenesis of AD (see figure 1). Abnormal deposition of highly insoluble protein aggregates or inclusion bodies within nerve cells is commonly observed in nervous tissue in association with several chronic neurodegenerative diseases including AD [1]. These inclusion bodies show ubiquitin immunoreactivity in human AD brains, along with immunoreactivity to other proteins [24-27]. The accumulation of ubiquitin-protein conjugates in neuropathological lesions was first detected in NFTs isolated from human brain [28,29], and it is these NFTs that best correlate with the degree of dementia [30]. It has been shown that aggregated proteins in cell line experiments tend to inhibit the UPS [31,32]. Alterations in the UPS have been connected to several neurodegenerative diseases [2,33]; in some instances, mutations in specific genes have been linked to the etiology of the disease while in other cases impairment of the UPS could be a late event in pathogenesis [32]. Although the perturbations in UPS-mediated proteolysis lead to pleiotropic effects on neurons including cell death or degeneration, one of the early effects is believed to be synaptic malfunction [14]. Many recent reports from animal studies demonstrate a role for UPS-mediated degradation of numerous substrate proteins in synaptic plasticity, thus linking the UPS to normal synaptic function [2,34]. For example, a *Drosophila* study suggested that the UPS acutely regulates presynaptic protein turnover and synaptic efficacy [35]. The UPS can also regulate long-term synaptic plasticity by degrading a crucial CREB repressor in *Aplysia*, as shown by investigations in our laboratory [36].




Figure 1

Pathogenesis of Alzheimer's disease: potential roles of the ubiquitin proteasome system. The figure summarizes the two major hypotheses (A β and tau) of AD pathology and the linkage of UPS to AD pathogenesis. Extracellular amyloid plaques consisting of insoluble A β peptide and intracellular neurofibrillary tangles comprising hyperphosphorylated protein tau are the two major features evident in the post mortem AD brain. Although the figure depicts only increased production of A β_{42} (a splice variant of A β , some familial Alzheimer's disease (FAD) mutations in APP or PSEN 1 also lead to increased A β_{42} secretion [71]). The roles of the UPS in the steps leading to AD pathogenesis are shown in green boxes. The ubiquitin mutant UBB⁺¹ is also linked to AD, though it is unclear at present how pathogenesis mediated by UBB⁺¹ relates to the major AD hypotheses. Abbreviations used are: A β , amyloid β ; AD, Alzheimer's disease; APP, amyloid precursor protein; MAP, microtubule associated protein; PHFs, paired helical filaments; Ub, ubiquitin; UPS, ubiquitin proteasome system.

Disease models, knockouts, assays

The UPS and synaptic dysfunction in early Alzheimer's disease

Memory impairment in AD likely results from synaptic dysfunction, for example a defect in the ability to change synaptic strength or synaptic plasticity. The role of the UPS in synaptic plasticity was first observed in an invertebrate cellular model of long-term memory called long-term facilitation (LTF) [37]. Specifically, the regulatory subunits of PKA were found to be substrates for the UPS [37]. Also, *Aplysia* ubiquitin C-terminal hydrolase (Ap-uch), a homolog of vertebrate UCHL1 (ubiquitin carboxyl-terminal hydrolase isozyme L1), was found to enhance the degradation of polyubiquitylated R subunit of PKA by removing ubiquitin prior to degradation [38]. Direct electrophysiological experiments in which expression or function of Ap-Uch was perturbed demonstrated a crucial role for the hydrolase in LTF [38]. These studies have been corroborated by experiments on long-term memory in mice. Furthermore, synaptic dysfunction in hippocampal slices from APP/PSEN1 mice (an animal model of AD), or synaptic dysfunction in hippocampal slices from normal mice caused by treatment with oligomeric A β , was reversed by treatment with exogenous UCHL1 [39]. The basic research on the function of UCHL1 in synaptic plasticity [38], and the application of this observation to treat synaptic dysfunction in AD [39], suggests that perturbations in UPS components could be an important causative factor in AD.

A role for UCHL1 in AD has been supported by other observations. For example, the genetic defect in a mouse model of fragile axonal dystrophy (*gad*) was shown to be caused by an in-frame deletion that includes exons 7 and 8 of *Uchl1*, encoding UCHL1. The *gad* mice display ataxia (lack of coordination in muscular movements), characterized by dragging of the hind legs. In the sensory and motor neurons of *gad* mice, accumulation of A β and ubiquitin-positive deposits occurs in a manner reminiscent of AD pathology [40,41]. The studies by Osaka *et al.* [42] demonstrated that UCHL1 ensures ubiquitin stability within neurons. It was also shown that UCHL1 protein level is down-regulated in idiopathic Parkinson's disease (PD) as well as in AD brains [43]. Full-length UCHL1 appears to be a major target of oxidative damage in AD and PD brains, and the enzyme is extensively modified by carbonyl formation, methionine oxidation and cysteine oxidation [44]. Also, evidence from studies on Chinese Han population indicates a genetic association between a serine to tyrosine mutation (S18Y polymorphism) in *UCHL1* and sporadic AD. This study concluded that the Y allele and YY genotype of the S18Y polymorphism in *UCHL1* could confer a protective effect against sporadic AD in female subjects [45].

The UPS and proteolytic defects in Alzheimer's disease

The ubiquitylated protein aggregates found in AD brains are likely to result from a malfunction or overload of the UPS or from structural changes in the protein substrates, halting their degradation. The presence of ubiquitylated proteins in all the AD cases [24,46,47] leads us to speculate that AD is associated with an inability of neurons to degrade specific proteins or accumulated protein aggregates. The following outlines how such a defect in the UPS could occur.

A ubiquitin-conjugating enzyme, E2-25K/HIP-2, was reported to be a mediator of A β -mediated toxicity and proteasome inhibition in an animal model containing APP mutations [48]. A ubiquitin mutant, UBB⁺ (a potent proteasome inhibitor observed in AD brains), was also found to functionally interact with E2-25K/HIP-2-mediated neurotoxicity [48]. In *in vitro* experiments, it was observed that A β could bind and inhibit the proteasome, thus blocking degradation of ubiquitin-conjugated proteins [49,50]. Furthermore, intraneuronally accumulated A β peptide in an APP/PSEN1 mutant neuronal cell culture was also shown to inhibit both the proteasome and deubiquitylating enzymes (DUBs) [51]. Ubiquitin immunoreactivity detected in axonal spheroids and dendritic compartments is associated with the elevated intraneuronal A β peptide and axonopathy observed in a transgenic mouse model of mutant APP/PSEN1 [52,53]. Results emerging from these studies support the idea that A β peptide's toxicity could be due to interference with ubiquitin conjugation or direct interaction with the proteasome itself.

It is also proposed that other causative factors in AD, such as paired helical filaments (PHFs) of tau protein, impair proteasome function [31]. In the brains of AD patients, proteasome function was shown to be reduced mostly in areas crucial for long-term memory formation such as the hippocampus, parahippocampal gyrus superior, middle temporal gyri and inferior parietal lobule, but not in other areas such as the occipital lobe [54]. Another study showed that PHFs of tau in brains of AD patients, as well as *in vitro* assembly of PHFs using human recombinant tau protein, both inhibited proteasome activity [55].

Taken together, evidence from the studies on early cognitive impairment in AD patients and animal models of AD, and the investigations on impairment of the UPS in AD, support a role for impairment of proteolysis in early synaptic dysfunction. Furthermore, there is considerable evidence supporting a role for the UPS in synaptic plasticity [2]. Although a secondary role for the UPS in AD pathology cannot be ruled out, given the role of the UPS in synaptic plasticity and in maintaining the integrity of the synapse, perturbations in these functions could be a pri-

mary cause of synaptic dysfunction and eventual synaptic loss in this disease.

The presence of ubiquitin and its association with tau in NFTs and senile plaques is a common factor in cases of AD [1]. Accumulated ubiquitin is also present in Lewy bodies, characteristic to some forms of the disease [26]. In all these cases, the role of tau and other putative target proteins in the pathogenesis of the disease is not understood. Also, it is still not clear whether aberration in proteolysis plays a causative role or only a secondary role, as described above [56]. Conflicting reports also exist on the E3 that ubiquitylates tau. Two reports claim that the ubiquitin ligase CHIP (carboxyl terminus of Hsp 70-interacting protein) targets the protein for degradation [57,58], whereas another study argues that the ubiquitin ligase TRAF6 is involved [59]. The discrepancy in the results could perhaps be resolved if the phosphorylation state of tau and the type of ubiquitin linkage that occurs with each ligase was known. CHIP has been shown to target hyperphosphorylated tau and TRAF6 to polyubiquitylate tau via Lys63 of ubiquitin (normally, polyubiquitylation occurs through Lys48 linkage). Thus, the two ligases could act on the same substrate under different conditions.

A more direct relationship between the ubiquitin system and pathogenesis of AD was established with the discovery of a frameshift mutation in the ubiquitin transcript, which results in ubiquitin with 20 extra amino acid residues at its C-terminus (UBB⁺¹). The UBB⁺¹ protein has been observed in the brains of AD patients [60]. UBB⁺¹ is an efficient substrate for polyubiquitylation; however, it forms polyubiquitin chains that cannot be disassembled by DUBs. Polyubiquitin chains with UBB⁺¹ potentially inhibit the 26S proteasomal degradation of a substrate to which they are attached [61]. This report also suggests that the inhibitory activity of UBB⁺¹ could be an important determinant of neurotoxicity and that it contributes to an environment that favors the accumulation of misfolded proteins [62,63].

In addition, other proteins implicated in AD, such as presenilins (PSENs) 1 and 2 (which are crucial for processing APP), are linked to the UPS. Specifically, both PSEN1 and PSEN2 are targets for UPS-mediated degradation [64]. It is not known, however, whether aberration in the degradation of PSEN1 and PSEN2 plays any role in the pathogenesis of AD.

Disease targets and ligands

Development of therapeutic approaches and drugs that target components of the UPS would require a better understanding of the role of proteolysis in AD progression. There are many potential drug targets in the UPS, such as ubiquitin-conjugating enzymes, DUBs and the

proteasome. Among the enzymes that conjugate ubiquitin to substrates, E3s are the best potential therapeutic targets because they mainly determine substrate specificity. Since the substrate binding region imparts specificity to E3s, allosteric modification of this region by small molecules, so that specific E3s have either increased or decreased affinity towards specific substrates, is one way of controlling accumulation of the ubiquitylated substrate [33]. Selective engineering of UPS components that enables modification of their delivery to a specific affected region and subsequent degradation of specific accumulated ubiquitylated proteins or protein aggregates, could provide an alternative approach to small allosteric molecules [33]. However, to date, no strong E3 candidate has been implicated in AD.

DUBs could also be potential drug targets if a definite role for these enzymes in AD is established. Modulation of specific DUBs by small molecules to enhance the deubiquitylation of polyubiquitin chains of mutant UBB⁺¹ could be another possibility as these chains inhibit proteasomes in the AD brain [61]. A potential alternative strategy is to exploit the role of DUBs in synaptic plasticity to counteract the adverse effects on this process in the AD brain. For example, UCHL1 administration was utilized to rescue synaptic function [39] based on previous studies on the role of this protein in synaptic plasticity [38].

Another unexplored area for drug discovery is activation of the proteasome. Although many inhibitors of the proteasome are available, no effective drugs exist that can enhance the function of the proteasome. Since abnormal protein aggregation and proteasome inhibition is a common feature of AD and other neurodegenerative diseases, enhancement of proteasome activity by small molecules could be an efficient way to remove the aggregates that accumulate in the brain [33]. Removal of protein aggregates by the proteasome could be achieved by employing the following strategies: (1) by increasing the activity of the proteasome through up-regulating assembly of the 19S and 20S complexes; (2) by stimulating the recognition of ubiquitylated proteins in protein aggregates; (3) by overexpressing or modulating the chaperone activity of either chaperonins or ATPase subunits of 19S to unfold the aggregated proteins and (4) by stimulating the catalytic activity of the 20S core of the proteasome using small molecules [33]. Supporting this idea, a study showed that resveratrol, a naturally occurring polyphenol found in grapes and red wine, lowers the levels of A β in cell lines by promoting its proteasome-dependent degradation. This suggests a possible use for this compound in therapeutic intervention in AD [65].

With respect to ligands that modulate UPS components, there has been little progress. Even though proteasome

inhibitors are being tested in clinical trial for cancer therapy [66], such compounds cannot be used in the nervous system because the role of the UPS in this system is more complex than in cancer [2,67]. As such, non-selective proteasome inhibition as a therapeutic strategy for neurodegenerative diseases could have many undesired side effects.

New frontiers in drug discovery

Although several studies suggest a role for the UPS in AD, systematic and thorough studies are necessary to pinpoint how each component of the UPS could be linked to synaptic dysfunction or neurodegeneration in AD. Genetic evidence indicates that disruption of ubiquitin-mediated processes can lead to neurodegeneration; however, the relationship between the UPS and idiopathic neurodegenerative disorders is less clear. Basic research on the role of the UPS in normal brain function is likely to guide investigations into the links between UPS components and AD, which will allow identification of potential drug targets. Also, studies on genetic polymorphisms within UPS components, combined with functional validation in animal models, are likely to aid our understanding of how impairment of proteolysis contributes to pathogenesis of AD. This in turn will aid the development of therapeutic strategies. For example, even though polymorphisms in the intron of *SEL1L*[68], which encodes a component of the endoplasmic reticulum stress degradation pathway, have been found in Italian sporadic AD patients, it is not clear whether such polymorphisms have any effect on proteolysis. Similarly, it remains to be determined whether upregulation in AD brains of dactylidin, a putative RING finger ubiquitin ligase, has any functional consequences [69]. Since ubiquitin-like proteins play a role in the formation and regulation of autophagosomes [70], modulation of this autophagic-lysosomal pathway by UPS components could be another potential therapeutic strategy for removal of abnormal aggregated proteins seen in AD. A key area that requires further research is the development of small molecules to modulate the function of UPS components.

The role of the UPS in neurodegenerative diseases, including its connection to AD, is an intensive area of research worldwide. Proteolysis by the UPS is essential to normal cellular function and survival. Thus, it will be important to distinguish the roles of UPS components in specific neuronal functions and abnormalities such that a fuller understanding of UPS malfunction in diseases like AD can be obtained and therapeutic interventions be designed.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

This article has been published as part of *BMC Biochemistry* Volume 8 Supplement 1, 2007: Ubiquitin-Proteasome System in Disease Part I. The full contents of the supplement are available online at <http://www.biomedcentral.com/1471-2091/8?issue=S1>.

References

1. Ciechanover A, Brundin P: **The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg.** *Neuron* 2003, **40**:427-446.
2. Hegde AN: **Ubiquitin-proteasome-mediated local protein degradation and synaptic plasticity.** *Prog Neurobiol* 2004, **73**:311-357.
3. Bartus RT, Dean RL III, Beer B, Lippa AS: **The cholinergic hypothesis of geriatric memory dysfunction.** *Science* 1982, **217**:408-414.
4. Graeber MB, Kosel S, Egensperger R, Banati RB, Muller U, Bise K, et al.: **Rediscovery of the case described by Alois Alzheimer in 1911: historical, histological and molecular genetic analysis.** *Neurogenetics* 1997, **1**:73-80.
5. Mattson MP: **Pathways towards and away from Alzheimer's disease.** *Nature* 2004, **430**:631-639.
6. Moller HJ, Graeber MB: **The case described by Alois Alzheimer in Historical and conceptual perspectives based on the clinical record and neurohistological sections.** *Eur Arch Psychiatry Clin Neurosci* 1998, **248**:111-122.
7. Perry G, Rizzuto N, Utilio-Gambetti L, Gambetti P: **Paired helical filaments from Alzheimer disease patients contain cytoskeletal components.** *Proc Natl Acad Sci U S A* 1985, **82**:3916-3920.
8. Selkoe DJ: **The molecular pathology of Alzheimer's disease.** *Neuron* 1991, **6**:487-498.
9. Blennow K, de Leon MJ, Zetterberg H: **Alzheimer's disease.** *Lancet* 2006, **368**:387-403.
10. Iwata N, Higuchi M, Saido T: **Metabolism of amyloid-beta peptide and Alzheimer's disease.** *Pharmacology & Therapeutics* 2005, **108**:129-148.
11. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: **Amyloid plaque core protein in Alzheimer disease and Down syndrome.** *Proc Natl Acad Sci U S A* 1985, **82**:4245-4249.
12. Selkoe DJ: **Alzheimer's disease: genes, proteins, and therapy.** *Physiol Rev* 2001, **81**:741-766.
13. Hardy J, Selkoe D: **The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.** *Science* 2002, **297**:353-356.
14. Selkoe D: **Alzheimer's disease is a synaptic failure.** *Science* 2002, **298**:789-791.
15. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al.: **Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.** *Ann Neurol* 1991, **30**:572-580.
16. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, et al.: **Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models.** *Proc Natl Acad Sci U S A* 1999, **96**:3228-3233.
17. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al.: **High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.** *J Neurosci* 2000, **20**:4050-4058.
18. Larson J, Lynch G, Games D, Seubert P: **Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice.** *Brain Research* 1999, **840**:23-35.
19. Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, et al.: **Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain.** *Journal of Biological Chemistry* 1999, **274**:6483-6492.
20. Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M: **Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling.** *Proc Natl Acad Sci U S A* 2002, **99**:13217-13221.

21. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al.: **Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.** *Science* 1996, **274**:99-102.
22. Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, et al.: **Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice.** *Nature Neuroscience* 1999, **2**:271-276.
23. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al.: **Naturally secreted oligomers of amyloid beta protein potentially inhibit hippocampal long-term potentiation in vivo.** *Nature* 2002, **416**:535-539.
24. Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett HB, et al.: **Frontotemporal dementia: clinicopathological correlations.** *Ann Neurol* 2006, **59**:952-962.
25. Layfield R, Lowe J, Bedford L: **The ubiquitin-proteasome system and neurodegenerative disorders.** *Essays Biochem* 2005, **41**:157-171.
26. Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billett M, et al.: **Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease.** *J Pathol* 1988, **155**:9-15.
27. Mayer RJ, Tipler C, Arnold J, Laszlo L, Al-Khedhairi A, Lowe J, et al.: **Endosome-lysosomes, ubiquitin and neurodegeneration.** *Adv Exp Med Biol* 1996, **389**:261-269.
28. Mori H, Kondo J, Ihara Y: **Ubiquitin is a component of paired helical filaments in Alzheimer's disease.** *Science* 1987, **235**:1641-1644.
29. Perry G, Friedman R, Shaw G, Chau V: **Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains.** *Proc Natl Acad Sci U S A* 1987, **84**:3033-3036.
30. Braak H, Braak E: **Neuropathological staging of Alzheimer-related changes.** *Acta Neuropathol (Berl)* 1991, **82**:239-259.
31. Johnston JA, Ward CL, Kopito R: **Aggresomes: a cellular response to misfolded proteins.** *J Cell Biol* 1998, **143**:1883-1898.
32. Layfield R, Cavey JR, Lowe J: **Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders.** *Ageing Res Rev* 2003, **2**:343-356.
33. Upadhy SC, Hegde A: **Ubiquitin-proteasome pathway components as therapeutic targets for CNS maladies.** *Curr Pharm Des* 2005, **11**:3807-3828.
34. Bingol B, Schuman E: **Synaptic protein degradation by the ubiquitin proteasome system.** *Curr Opin Neurobiol* 2005, **15**:536-541.
35. Speese SD, Trotta N, Rodesch CK, Aravamudan B, Broadie K: **The ubiquitin proteasome system acutely regulates presynaptic protein turnover and synaptic efficacy.** *Curr Biol* 2003, **13**:899-910.
36. Upadhy SC, Smith TK, Hegde A: **Ubiquitin-proteasome-mediated CREB repressor degradation during induction of long-term facilitation.** *J Neurochem* 2004, **91**:210-219.
37. Hegde AN, Goldberg AL, Schwartz J: **Regulatory subunits of cAMP-dependent protein kinases are degraded after conjugation to ubiquitin: a molecular mechanism underlying long-term synaptic plasticity.** *Proc Natl Acad Sci U S A* 1993, **90**:7436-7440.
38. Hegde AN, Inokuchi K, Pei W, Casadio A, Ghirardi M, Chain DG, et al.: **Ubiquitin C-terminal hydrolase is an immediate-early gene essential for long-term facilitation in Aplysia.** *Cell* 1997, **89**:115-126.
39. Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, Staniszewski A, et al.: **Ubiquitin Hydrolase Uch-L1 Rescues beta-Amyloid-Induced Decreases in Synaptic Function and Contextual Memory.** *Cell* 2006, **126**:775-788.
40. Ichihara N, Wu J, Chui DH, Yamazaki K, Wakabayashi T, Kikuchi T: **Axonal Degeneration Promotes Abnormal Accumulation of Amyloid Beta-Protein in Ascending Gracile Tract of Gracile Axonal Dystrophy (Gad) Mouse.** *Brain Research* 1995, **695**:173-178.
41. Wu J, Ichihara N, Chui DH, Yamazaki K, Kikuchi T: **[Ubiquitin immunoreactivity in the central nervous system of gracile axonal dystrophy (GAD) mouse].** *No To Shinkei* 1995, **47**:881-885.
42. Osaka H, Wang YL, Takada K, Takizawa S, Setsuie R, Li H, et al.: **Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron.** *Hum Mol Genet* 2003, **12**:1945-1958.
43. Barrachina M, Castano E, Dalfo E, Maes T, Buesa C, Ferrer I: **Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with Lewy bodies.** *Neurobiol Dis* 2006, **22**:265-273.
44. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, et al.: **Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases.** *J Biol Chem* 2004, **279**:13256-13264.
45. Xue S, Jia J: **Genetic association between Ubiquitin Carboxy-terminal Hydrolase-L1 gene S18Y polymorphism and sporadic Alzheimer's disease in a Chinese Han population.** *Brain Res* 2006, **1087**:28-32.
46. van Leeuwen FW, van TP, Sonnemans MA, Hobo B, Mann DM, Van BC, et al.: **Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies.** *Neurology* 2006, **66**:S86-S92.
47. Wang LN, Zhu MW, Gui QP, Li X: **[An analysis of the causes of dementia in 383 elderly autopsied cases].** *Zhonghua Nei Ke Za Zhi* 2003, **42**:789-792.
48. Song S, Kim SY, Hong YM, Jo DG, Lee JY, Shim SM, et al.: **Essential role of E2-25K/Hip-2 in mediating amyloid-beta neurotoxicity.** *Mol Cell* 2003, **12**:553-563.
49. Shringarpure R, Grune T, Sitte N, Davies K: **4-Hydroxynonenal-modified amyloid-beta peptide inhibits the proteasome: possible importance in Alzheimer's disease.** *Cell Mol Life Sci* 2000, **57**:1802-1809.
50. Gregori L, Hainfeld JF, Simon MN, Goldgaber D: **Binding of amyloid beta protein to the 20 S proteasome.** *J Biol Chem* 1997, **272**:58-62.
51. Almeida CG, Takahashi RH, Gouras G: **Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system.** *J Neurosci* 2006, **26**:4277-4288.
52. Wirths O, Weis J, Kaye R, Saido TC, Bayer T: **Age-dependent axonal degeneration in an Alzheimer mouse model.** *Neurobiol Aging* 2006.
53. Wirths O, Weis J, Szczygielski J, Multhaup G, Bayer T: **Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer's disease.** *Acta Neuropathol (Berl)* 2006, **111**:312-319.
54. Keller JN, Hanni KB, Markesbery W: **Impaired proteasome function in Alzheimer's disease.** *J Neurochem* 2000, **75**:436-439.
55. Keck S, Nitsch R, Grune T, Ullrich O: **Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease.** *J Neurochem* 2003, **85**:115-122.
56. Bossy-Wetzell E, Schwarzenbacher R, Lipton S: **Molecular pathways to neurodegeneration.** *Nat Med* 2004:S2-S9.
57. Dickey CA, Yue M, Lin WL, Dickson DW, Dunmore JH, Lee WC, et al.: **Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species.** *J Neurosci* 2006, **26**:6985-6996.
58. Sahara N, Murayama M, Mizoroki T, Urushitani M, Imai Y, Takahashi R, et al.: **In vivo evidence of CHIP up-regulation attenuating tau aggregation.** *J Neurochem* 2005, **94**:1254-1263.
59. Babu JR, Geetha T, Wooten M: **Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation.** *J Neurochem* 2005, **94**:192-203.
60. van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, Sluijs JA, et al.: **Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients.** *Science* 1998, **279**:242-247.
61. Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R, et al.: **Inhibition of the ubiquitin-proteasome system in Alzheimer's disease.** *Proc Natl Acad Sci U S A* 2000, **97**:9902-9906.
62. de PR, Fischer DF, Maat-Schieman ML, Hobo B, de Vos RA, Brunt ER, et al.: **Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases.** *Hum Mol Genet* 2004, **13**:1803-1813.
63. Lindsten K, de Vrij FM, Verhoef LG, Fischer DF, van Leeuwen FW, Hol EM, et al.: **Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation.** *J Cell Biol* 2002, **157**:417-427.
64. Kim TW, Pettingell WH, Hallmark OG, Moir RD, Wasco W, Tanzi R: **Endoproteolytic cleavage and proteasomal degradation of**

- presenilin 2 in transfected cells. *J Biol Chem* 1997, **272**:11006-11010.
65. Marambaud P, Zhao H, Davies P: **Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides.** *J Biol Chem* 2005, **280**:37377-37382.
66. Adams J, Kauffman M: **Development of the proteasome inhibitor Velcade (Bortezomib).** *Cancer Invest* 2004, **22**:304-311.
67. Upadhy SC, Ding L, Smith TK, Hegde A: **Differential regulation of proteasome activity in the nucleus and the synaptic terminals.** *Neurochem Int* 2006, **48**:296-305.
68. Saltini G, Dominici R, Lovati C, Cattaneo M, Michelini S, Malferrari G, et al.: **A novel polymorphism in SEL1L confers susceptibility to Alzheimer's disease.** *Neurosci Lett* 2006, **398**:53-58.
69. von Rotz RC, Kins S, Hipfel R, von der KH, Nitsch R: **The novel cytosolic RING finger protein dactylidin is up-regulated in brains of patients with Alzheimer's disease.** *Eur J Neurosci* 2005, **21**:1289-1298.
70. Klionsky DJ, Emr S: **Autophagy as a regulated pathway of cellular degradation.** *Science* 2000, **290**:1717-1721.
71. Murayama O, Tomita T, Nihonmatsu N, Murayama M, Sun X, Honda T, et al.: **Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease.** *Neurosci Lett* 1999, **265**:61-63.

Publication history

Republished from Current BioData's Targeted Proteins database (TPdb; <http://www.targetedproteinsdb.com>).

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

